A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson’s Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components

– Is able to read, understand, and provide written, dated informed consent prior to
Screening Visit.

– Is male or female, between 18 and 80 years of age at Screening Visit.

– Is diagnosed with idiopathic PD that meets UK Parkinson’s Disease Society (UKPDS)
Brain Bank Clinical Diagnostic Criteria and requires treatment with and shows
responsiveness to levodopa.

– Has experienced dyskinesia over a period of at least 3 months prior to Screening Visit

– Has stable peak-effect dyskinesia

– Has more than one hour of “ON” time with troublesome dyskinesia during daily waking
hours on a 24-hour PD subject diary

– Is on a stable levodopa dosing regimen requiring at least 3 dose administrations but
no more than 6 dose administrations per day

Exclusion Criteria:

– Has undergone surgery for the treatment of PD

– Has a current diagnosis of Substance Use (including alcohol) Disorder (Abuse or
Dependence, as defined by Diagnostic and Statistical Manual, Fifth Edition [DSM 5]),

– Has psychiatric diagnosis of acute psychotic disorder or other psychiatric diagnoses

– Has a significant risk for suicidal behavior in the opinion of the investigator during
the course of their participation in the study

– Has current seizure disorders (other than febrile seizures in childhood) requiring
treatment with anticonvulsants.

– Has known serious ongoing symptomatic cerebral disease or cerebrovascular disease or
any acute brain trauma requiring treatment with anti-convulsant therapy within 5 years
prior Visit 2, Week 0 (Baseline Visit).

– Has a history of exclusively diphasic, OFF state, myoclonic, dystonic, or akathetic
dyskinesia without peak-dose dyskinesia.

Other criteria related to other medical conditions to be referred to the protocol.